Kristin Weber
Family · Minneapolis, MNNPI 1487710067
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Takeda Pharmaceuticals U.S.A., Inc. accounts for 92.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $13,588 and has fallen 68.4% since, to $4,288 in 2025. Among family clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $298.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$33K
- Biocryst Pharmaceuticals, Inc.$2K
- Octapharma USA, Inc.$233
- Amgen$136
- CSL Behring$123
- Cycle Pharmaceuticals Inc$87
- plus $622 from 18 others
What the payments were for
- Consulting fees$15,60544%
- Speaking & faculty fees$14,53741%
- Travel & lodging$3,77811%
- Food & beverage$1,5214%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 66 | $32,657 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,608 |
| Octapharma USA, Inc. | 6 | $233 |
| Amgen(2 entities) | 2 | $136 |
| CSL Behring | 4 | $123 |
| Cycle Pharmaceuticals Inc | 3 | $87 |
| AstraZeneca | 4 | $68 |
| GSK | 4 | $65 |
| Pfizer | 3 | $59 |
| AbbVie | 3 | $54 |
| Biocryst US Sales Co., LLC | 4 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| LEO Pharma Inc. | 2 | $44 |
| ADMA Biomanufacturing LLC | 3 | $42 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Baxter Healthcare | 1 | $32 |
| Incyte Corporation | 1 | $25 |
| Novartis | 1 | $23 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Optinose US, Inc. | 1 | $14 |
| Genentech USA, Inc. | 2 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,466 in reported general payments places this provider in the 95th percentile of 1,121 family providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vancomycin Hcl | 30 | $5,504 |
| Amoxicillin | 102 | $1,705 |
| CefuroximeCefuroxime Axetil | 24 | $1,052 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 11 | $1,036 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 41 | $687 |
| Doxycycline Hyclate | 21 | $554 |
| Cephalexin | 17 | $369 |
| CeftriaxoneCeftriaxone Sodium | 12 | $333 |
| Omeprazole | 15 | $166 |
| Prednisone | 14 | $108 |
Paid to pharmacies, not to this prescriber.
Other family in Minneapolis
- Julia GourdeMinneapolis$65K
- Robin DontaMinneapolis$60K
- Kathleen FredellMinneapolis$28K
- Diana CzelMinneapolis$24K
- Elisa RiveroMinneapolis$16K
- Marcia SimmondsMinneapolis$10K
- Rachel StenachMinneapolis$7K
- Regina SoehnleinMinneapolis$5K
- Kathryn TietzMinneapolis$3K
- Ashley EnglishMinneapolis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.